Editors in Conversation
Is the future of cervical cancer screening non-invasive? Sharmila Manjeshwar, Ph.D. and Jeffrey Klausner M.D. MPH, discuss a breakthrough in HPV diagnostics: urine-based testing. While vaccination and clinical screening have reduced cervical cancer rates, participation has stalled due to barriers like healthcare access and the invasive nature of traditional clinician-collected samples. This conversation explores how novel high-volume urine concentration technology is changing the landscape, making screening more accessible, private, and efficient. Watch this episode:...
info_outlineEditors in Conversation
Most microbiome research focuses on soil, oceans, or hosts. But the atmosphere itself harbors diverse communities of bacteria and fungi that move between ecosystems. This episode explores a recent mBio study comparing airborne microbial communities above a subalpine forest and a grassland in Colorado. The conversation unpacks what the “aerobiome” is, how scientists actually sample microbes from the air, and why height, time of day, and season matter. The study reveals striking differences between fungi and bacteria, with fungi showing strong site-specific structure and environmental...
info_outlineEditors in Conversation
Matrix-assisted laser desorption ionization time of flight mass spectrometry (or MALDI) has revolutionized the clinical microbiology laboratory, enabling rapid, accurate and cheap identification of bacteria, yeast, moulds and mycobacteria. In most labs, it has become a verb (I maldi’ed it). But – can it replace our antimicrobial susceptibility tests? Let’s find out! Guests: Dr. Frieder Schaumburg Niklas Wiesmann
info_outlineEditors in Conversation
In the inaugural episode of Editors in Conversation mBio edition, Marvin Whiteley speaks with Arturo Casadevall, infectious-disease physician-scientist, founding Editor in Chief of mBio, and a leading voice in fungal pathogenesis and scientific rigor. They explore how climate change may be reshaping the fungal kingdom, potentially eroding the thermal barrier that has historically protected humans from most fungal pathogens. Using Candida auris (C auris) as a case study, they discuss heat adaptation, antifungal resistance, and what climate change could mean for future outbreaks. The...
info_outlineEditors in Conversation
The Interdisciplinary Meeting of Antimicrobial Resistance and Innovation has launched! The first version of IMARI brought together researchers, clinicians, industry leaders and policymakers to address one of the greatest challenges in modern medicine: antimicrobial resistance” Check the highlights at IMARI.org and prepare for IMARI 2017 from January 27-29, 2027! The inaugural amazing conference took place in Las Vegas. This is the forst time that ASM and IDSA collaborate together in a scientific meeting. One of the sessions involved an unprecedent collaboration between two journals AAC and...
info_outlineEditors in Conversation
Climate change is one of the most pressing issues facing humanity – and is not a future problem. Changes to the Earth’s climate driven by emission of greenhouse gases have led to glaciers shrinking, plant and animal geographic ranges shifting and historical droughts, wildfires and rainfall. What does all of this have to do with the clinical laboratory? Subscribe to Editors in Conversation on , , , or and never miss an episode. Guests: , Director of Clinical Chemistry and Associate Professor at VUMC , bioMérieux Links: : an ASM Laboratory Practices Subcommittee...
info_outlineEditors in Conversation
This is a special live recording of Editors in Conversation at the 2025 ASM Global Research Symposium in Bengaluru, India. We explore the evolving landscape of drug-resistant pathogens—from the intracellular survival strategies of Salmonella to the global rise of multidrug-resistant fungi like Candida auris. This conversation highlights the urgent need for integrated, One Health solutions to combat AMR across human, animal, and environmental domains. Watch this episode: https://youtu.be/G1KtS6MSjHs Topics discussed: The implications of the OneHealth approach for microbiology and...
info_outlineEditors in Conversation
I almost can’t believe that we are wrapping up yet another year on the podcast this month, which has been going strong for 6 years now! And it has been another exciting year in the world of Clin Micro as well with improvements and new assays available for some of our bread and butter tests, but the year also brought about significant developments in the application of AI and digital imaging, use of NGS methods, and probably some cool AST stuff in there too among other things, with many of these advancements published in JCM. And so, as has become customary for the last 6 years, for this...
info_outlineEditors in Conversation
Prosthetic joint infections (PJI) remain among the most devastating complications in orthopedic surgery, with increasing incidence paralleling the growth in arthroplasty procedures worldwide. While treatment protocols are well-established, evidence supporting current approaches is lacking, and outcomes remain suboptimal, highlighting the need for improved therapeutic strategies. AAC recently published a minireview of randomized controlled trials and emerging evidence for the management for these difficult to treat infection. Today, we discuss with one of the authors of the manuscript and an ID...
info_outlineEditors in Conversation
It’s that time of year, folks! No, not leaf-peeping season, or pumpkin spice season or even apple picking season – I’m talking respiratory virus season! The symphony of sniffles and coughs is just around the corner! It’s the time of year that clinical laboratories are stocking up on supplies, developing testing algorithms and putting out communications to try to convince people that every kid with the sniffles does not, in fact, warrant a highly-multiplexed respiratory virus panel test. The diagnostic landscape for respiratory viruses has evolved dramatically in the last five years,...
info_outlineTuberculosis is one of the most deadly infectious diseases that still causes significant burden of disease, particularly in the developing world. The emergence of resistance to first line agents severely limits the therapeutic options and threaten the ability to control dissemination of this disease. Fortunately, new drugs and regimens are now emerging as important alternatives against these organisms. Today, we will discuss this topic with outstanding experts in the field. Welcome to the editors in conversation.
Topics discussed:
- The burden of multidrug-resistant TB.
- New drugs and regimens for MDR TB.
- The current and future pipeline for TB
Guests:
- Kelly Dooley, MD Ph.D. Professor and Addison B. Scoville, Jr., Chair in Medicine, Director, Division of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center. Past Editor of AAC
- Sean Wasserman, MD Ph.D, Reader in Infectious Diseases at St Georges University of London and Associate Professor in the Division of Infectious Diseases and HIV Medicine at University of Cape Town, SA. Editor of AAC.
This episode is brought to you by the Antimicrobial Agents and Chemotherapy journal available at aac.asm.org. If you plan to publish in AAC, ASM Members get up to 50% off publishing fees. Visit asm.org/membership to sign up.
Visit journals.asm.org/journal/aac to browse issues and/or submit a manuscript.
Subscribe to Editors in Conversation (free) on Apple Podcasts, Google Podcasts, Android, Spotify, Email.